Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Janusz Jankowski, Richard H Hunt

Abstract

Aspirin is the best chemoprevention agent for colorectal cancer risk reduction despite the fact that the evidence for a decrease in mortality is weak. The cyclooxygenase-2 selective agents (COXIBS) have an efficacy similar to that of aspirin for most gastrointestinal (GI) lesions but not esophagus. Specifically, there are beneficial short term effects of COXIBs on the risk of colorectal adenoma as shown in the Approve, PreSAP, and APC studies. However, there is still an increased risk of upper GI complications with COXIBs when compared with placebo, and this risk may increase further in some people when aspirin is also consumed. Whereas aspirin reduces the risk of cardiovascular events, COXIBs and most traditional nonsteroidal anti-inflammatory drugs (but not all) are both associated with an increased risk of thrombotic cardiovascular events compared with placebo. In conclusion, COXIBs have a niche role for patients with familial adenomatous polyposis. The value of aspirin remains with respect for efficacy, mainly in the esophagus, and the side effect profile, especially in the elderly if given with acid suppression therapy. COXIBs should be used in younger populations, but if they are considered in the elderly because of incre...Continue Reading

References

Aug 15, 1994·Annals of Internal Medicine·E GiovannucciW C Willett
Mar 1, 1994·Epidemiology·D M Schreinemachers, R B Everson
Aug 4, 1993·Journal of the National Cancer Institute·P H GannC H Hennekens
May 6, 1993·The New England Journal of Medicine·F M GiardielloG J Offerhaus
Dec 16, 1998·Annals of Internal Medicine·T StürmerC H Hennekens
Jun 30, 2000·The New England Journal of Medicine·G SteinbachG Kelloff
Aug 31, 2001·JAMA : the Journal of the American Medical Association·D MukherjeeE J Topol
Apr 5, 2002·The New England Journal of Medicine·Francis M GiardielloStanley R Hamilton
Jan 10, 2003·The Cochrane Database of Systematic Reviews·E Berge, P Sandercock
Mar 7, 2003·The New England Journal of Medicine·Robert S SandlerRichard Schilsky
Mar 7, 2003·The New England Journal of Medicine·John A BaronRosalind U van Stolk
Dec 5, 2003·Journal of the National Cancer Institute·Wei Hong WangBenjamin Chun-Yu Wong
Jun 16, 2004·CA: a Cancer Journal for Clinicians·Anne S TsaoWaun Ki Hong
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Feb 17, 2005·The New England Journal of Medicine·Scott D SolomonUNKNOWN Adenoma Prevention with Celecoxib (APC) Study Investigators
Jun 18, 2005·BMJ : British Medical Journal·Colin Baigent
Jul 7, 2005·JAMA : the Journal of the American Medical Association·Nancy R CookJulie E Buring
Jul 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Mairi MacarthurEmad M El-Omar
Aug 25, 2005·JAMA : the Journal of the American Medical Association·Andrew T ChanCharles S Fuchs
Sep 1, 2006·The New England Journal of Medicine·Monica M BertagnolliUNKNOWN APC Study Investigators
Sep 1, 2006·The New England Journal of Medicine·Nadir ArberUNKNOWN PreSAP Trial Investigators
Nov 8, 2006·Gastroenterology·John A BaronUNKNOWN APPROVe Trial Investigators
Jan 30, 2007·Gastroenterology·Luis A García Rodríguez, Laura Barreales Tolosa
Mar 29, 2007·Archives of Internal Medicine·Andrew T ChanCharles S Fuchs
May 1, 2007·BMJ : British Medical Journal·Jae Hee KangFrancine Grodstein
May 25, 2007·The New England Journal of Medicine·Andrew T ChanCharles S Fuchs
Jun 7, 2007·Journal of the National Cancer Institute·Aditya BardiaJames R Cerhan
Jul 27, 2007·The New England Journal of Medicine·David J KerrUNKNOWN VICTOR Trial Group

❮ Previous
Next ❯

Citations

May 17, 2011·Lancet·Janusz JankowskiPaul Moayyedi
Mar 5, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Yoshifumi BabaShuji Ogino
Apr 16, 2009·Pharmacoepidemiology and Drug Safety·Jessica ChubakMargaret T Mandelson
Sep 29, 2011·Annals of the New York Academy of Sciences·Joel E RichterRichard H Hunt
Nov 6, 2014·Gastroenterology Research and Practice·Zhen WangJin-Lu Liu
Mar 12, 2009·Veterinary Pathology·S J BaekA M Legendre
Sep 3, 2010·The American Journal of Gastroenterology·Christine Cole JohnsonUNKNOWN PLCO Trial Team
Apr 20, 2011·The American Journal of Gastroenterology·Nadir ArberBernard Levin
Sep 9, 2008·The American Journal of Gastroenterology·Gary W Falk, Janusz Jankowski
Oct 13, 2011·British Journal of Cancer·J A Z Jankowski, P J Limburg
May 18, 2012·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Jeannette Y Wick
Jul 8, 2011·Cancer Prevention Research·Chan Young OckMyung-Hee Chung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Adenomatous Polyposis Coli

Adenomatous polyposis coli is a protein encoded by the APC gene and acts as a tumor suppressor. Discover the latest research on adenomatous polyposis coli here.